JPH0730042B2 - スルホンアミド類および薬物としてのそれらの使用 - Google Patents

スルホンアミド類および薬物としてのそれらの使用

Info

Publication number
JPH0730042B2
JPH0730042B2 JP4174993A JP17499392A JPH0730042B2 JP H0730042 B2 JPH0730042 B2 JP H0730042B2 JP 4174993 A JP4174993 A JP 4174993A JP 17499392 A JP17499392 A JP 17499392A JP H0730042 B2 JPH0730042 B2 JP H0730042B2
Authority
JP
Japan
Prior art keywords
methoxy
phenoxy
benzenesulfonamide
butyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP4174993A
Other languages
English (en)
Japanese (ja)
Other versions
JPH05222003A (ja
Inventor
カスパー・ブリ
マルテイヌ・クローゼル
バルター・フイシユリ
ジヨルジユ・ヒルト
ベルント−ミヒヤエル・レフラー
ヘンリ・ラムツ
ベルナー・ナイトハルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25687870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0730042(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JPH05222003A publication Critical patent/JPH05222003A/ja
Publication of JPH0730042B2 publication Critical patent/JPH0730042B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Bipolar Transistors (AREA)
  • Glass Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP4174993A 1991-06-13 1992-06-10 スルホンアミド類および薬物としてのそれらの使用 Expired - Fee Related JPH0730042B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH176091 1991-06-13
CH01516/92-6 1992-05-12
CH151692 1992-05-12
CH01760/91-0 1992-05-12

Publications (2)

Publication Number Publication Date
JPH05222003A JPH05222003A (ja) 1993-08-31
JPH0730042B2 true JPH0730042B2 (ja) 1995-04-05

Family

ID=25687870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4174993A Expired - Fee Related JPH0730042B2 (ja) 1991-06-13 1992-06-10 スルホンアミド類および薬物としてのそれらの使用

Country Status (34)

Country Link
US (1) US5292740A (enExample)
EP (1) EP0526708B1 (enExample)
JP (1) JPH0730042B2 (enExample)
KR (1) KR100235507B1 (enExample)
AT (1) ATE197044T1 (enExample)
AU (1) AU653604B2 (enExample)
BG (1) BG60831B2 (enExample)
BR (1) BR9202219A (enExample)
CA (1) CA2071193C (enExample)
CY (2) CY2306B1 (enExample)
CZ (1) CZ281434B6 (enExample)
DE (2) DE10299047I2 (enExample)
DK (1) DK0526708T3 (enExample)
DZ (1) DZ1587A1 (enExample)
EE (1) EE03028B1 (enExample)
ES (1) ES2152222T4 (enExample)
FI (1) FI112216B (enExample)
GR (1) GR3035162T3 (enExample)
HU (2) HU221203B1 (enExample)
IE (1) IE921920A1 (enExample)
IL (1) IL102138A (enExample)
IS (1) IS2054B (enExample)
LU (2) LU90976I2 (enExample)
MX (1) MX9202747A (enExample)
NL (1) NL300097I1 (enExample)
NO (2) NO303826B1 (enExample)
NZ (1) NZ243074A (enExample)
PT (1) PT526708E (enExample)
RO (1) RO111268B (enExample)
RU (1) RU2086544C1 (enExample)
SG (1) SG54209A1 (enExample)
SK (1) SK279006B6 (enExample)
TW (1) TW222625B (enExample)
ZA (1) ZA924126B (enExample)

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
UA26273A (uk) * 1989-08-30 1999-07-19 Ірвін Фокс Спосіб одержаhhя hосія із міhералу моhтморилоhіту для видалеhhя сірководhю та меркаптаhів вуглеводhів
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
TW224462B (enExample) * 1992-02-24 1994-06-01 Squibb & Sons Inc
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists
US5352800A (en) * 1993-03-11 1994-10-04 Merck & Co., Inc. Process for the production of a novel endothelin antagonist
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5374638A (en) * 1993-03-19 1994-12-20 Merck & Co., Inc. Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
US5334598A (en) * 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
FI941826L (fi) * 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
DE59409631D1 (de) * 1993-07-15 2001-02-15 Hoffmann La Roche Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
US6140325A (en) * 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
BR9407933A (pt) * 1993-11-01 1996-11-26 Japat Ltd Antagonistas de receptores de endotelina
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
EE9700209A (et) 1994-11-16 1998-04-15 Synaptic Pharmaceutical Corporation Dihüdropürimidiinid ja nende kasutamine
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US5837708A (en) * 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
WO1996016963A1 (de) * 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
CN1064965C (zh) * 1994-11-25 2001-04-25 弗·哈夫曼-拉罗切有限公司 新的磺酰胺类化合物及其作为药物的用途
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
TW313568B (enExample) * 1994-12-20 1997-08-21 Hoffmann La Roche
DK0799206T3 (da) * 1994-12-20 2003-01-27 Hoffmann La Roche Aryl- og heteroaryl-sulfonamidderivater, fremstillingen deraf og anvendelsen deraf som endothelinantagonister
RU2151767C1 (ru) * 1994-12-20 2000-06-27 Ф.Хоффманн-Ля Рош Аг Сульфонамиды и фармацевтическая композиция
PT801062E (pt) * 1994-12-28 2003-08-29 Kowa Co Derivados de pirimidina
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
DE19527568A1 (de) * 1995-07-28 1997-01-30 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE19528418A1 (de) * 1995-08-02 1997-02-06 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE69630799T2 (de) * 1995-09-06 2004-08-12 Kowa Co., Ltd., Nagoya Pyrimidinderivate
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
CZ260596A3 (en) * 1995-10-12 1997-12-17 Hoffmann La Roche Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
JP3087968B2 (ja) * 1995-12-20 2000-09-18 山之内製薬株式会社 アリールエテンスルホンアミド誘導体及びその医薬組成物
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
BR9708151A (pt) 1996-02-20 1999-07-27 Bristol Myers Squibb Co Processo para a preparaç o de bifenil isoxazol sulfonamidas
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
AU711936B2 (en) * 1996-08-09 1999-10-28 Banyu Pharmaceutical Co., Ltd. Stereoselective deoxygenation reaction
CA2265972A1 (en) * 1996-09-16 1998-03-26 Philip D. Acott Use of igf-i for the treatment of polycystic kidney disease and related indications
US5883254A (en) * 1996-11-08 1999-03-16 Hoffmann-La Roche Inc. Process for making pyrimidine derivatives
DE19653024A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5998625A (en) * 1997-01-14 1999-12-07 Merck & Co., Inc. Asymmetric conjugate addition reaction using a chiral additive
TW432028B (en) * 1997-01-14 2001-05-01 Merck & Co Inc Asymmetric conjugate addition reaction using a chiral additive
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
TR200202738T2 (tr) 1997-04-28 2003-03-21 Texas Biotechnology Corporation Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler
US6022972A (en) * 1997-08-08 2000-02-08 Merck & Co., Inc. Pyridine propanoic acid derivatives
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
EP1165472A4 (en) 1999-03-19 2002-11-20 Bristol Myers Squibb Co METHOD FOR PRODUCING BIPHENYL ISOXAZOLE
DE19916719A1 (de) * 1999-04-13 2000-10-19 Basf Ag Neue ECE-Inhibitoren, ihre Herstellung und Verwendung
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6720322B2 (en) * 1999-12-22 2004-04-13 Actelion Pharamceuticals Ltd. Butyne diol derivatives
AU3536701A (en) * 1999-12-22 2001-07-03 Actelion Pharmaceuticals Ltd Butyne diol derivatives
SK9532002A3 (en) 1999-12-31 2003-06-03 Texas Biotechnology Corp Sulfonamides and derivatives thereof that modulate the activity of endothelin
MXPA02007192A (es) * 2000-01-25 2002-12-09 Hoffmann La Roche Preparacion de sulfonamidas.
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6521632B2 (en) 2000-02-11 2003-02-18 Oy Juvantia Pharma Ltd Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor
BR0108221A (pt) * 2000-02-11 2003-03-05 Juvantia Pharma Ltd Oy Utilização de um antagonista alpha -2b- adrenoceptor seletivo para a manufatura de um preparado farmacêutico e processo para o tratamento ou prevenção de uma enfermidade mediada pelo alfa-2b-adrenoceptor em um mamìfero
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
MY140724A (en) * 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
PT1345920E (pt) 2000-12-18 2006-08-31 Actelion Pharmaceuticals Ltd Novas sulfonamidas e sua utilizacao como antagonistas dos receptores de endotelina
HUP0401076A2 (hu) * 2001-07-20 2004-09-28 Oy Juvantia Pharma Ltd. Alfa-2B-andrenoceptor antagonista vegyületek és alkalmazásuk gyógyszerkészítmények előállítására
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
FR2831446B1 (fr) * 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
EP1507756B1 (en) * 2002-05-24 2015-07-22 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
AU2003285321B2 (en) 2002-12-02 2010-04-08 Actelion Pharmaceuticals Ltd Pyrimidine-sulfamides and their use as endothelian receptor antagonist
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
JP2007529459A (ja) 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 治療に置けるレニン阻害剤の使用
CA2574958A1 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
NZ564167A (en) * 2005-05-17 2009-12-24 Actelion Pharmaceuticals Ltd Dispersible tablet comprising 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-benzenesulfonamide (bosutan)
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
WO2007031933A2 (en) * 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
JP2009513660A (ja) * 2005-10-26 2009-04-02 旭化成ファーマ株式会社 肺動脈性高血圧の治療用併用療法におけるファスジル
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
BRPI0708879A2 (pt) * 2006-03-13 2011-06-14 Encysive Pharmaceuticals peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica
EP2001446A2 (en) * 2006-03-13 2008-12-17 Encysive Pharmaceuticals, Inc Formulations of sitaxsentan sodium
US20100022568A1 (en) * 2006-04-13 2010-01-28 Actelion Pharmaceeuticals Ltd. Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
EP2049517B1 (en) 2006-07-20 2013-11-27 Novartis AG Amino-piperidine derivatives as cetp inhibitors
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US20080242687A1 (en) * 2007-04-02 2008-10-02 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
EP2150547A2 (en) * 2007-05-08 2010-02-10 Generics Ýuk¨Limited Polymorphic forms of bosentan
AU2008272685B2 (en) * 2007-06-29 2013-04-18 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US20090069351A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched bosentan
EP2205591A1 (en) * 2007-10-11 2010-07-14 Actavis Group PTC EHF Novel polymorphs of bosentan
NZ585438A (en) * 2007-10-24 2012-09-28 Generics Uk Ltd Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide
SI2207775T1 (sl) 2007-11-05 2012-05-31 Novartis Ag benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza
CN101878199B (zh) 2007-12-03 2013-09-18 诺瓦提斯公司 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物
ES2376375T3 (es) * 2007-12-18 2012-03-13 Dipharma Francis S.R.L. Procedimiento para la preparación de bosent�?n.
EP2248805A3 (en) 2008-01-01 2011-02-23 Cipla Ltd. Method of synthesis of bosentan, its polymorphic forms and its salts
WO2009095933A2 (en) * 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
WO2009093127A2 (en) * 2008-01-24 2009-07-30 Actavis Group Ptc Ehf Substantially pure and a stable crystalline form of bosentan
NZ587793A (en) * 2008-02-08 2012-06-29 Generics Uk Ltd Process for preparing bosentan
CN101279948B (zh) * 2008-03-14 2010-08-11 苏州博鸿化工技术有限公司 4,6-二氯-5-(2-甲氧基苯氧基)-2,2'-二嘧啶的合成方法
WO2009141167A1 (en) * 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
EP2307019A1 (en) * 2008-06-03 2011-04-13 Fresenius Medical Care Deutschland GmbH Pharmaceutical compositions comprising gamma secretase modulators
WO2010012637A1 (en) * 2008-08-01 2010-02-04 Inke, S.A. Process for the preparation of bosentan
WO2010015623A1 (en) * 2008-08-05 2010-02-11 Farmaprojects, S. A. Process for the preparation of endothelin receptor antagonists
WO2010032261A1 (en) * 2008-08-12 2010-03-25 Cadila Healthcare Limited Process for preparation of bosentan
CA2741928A1 (en) * 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
IT1393136B1 (it) 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan
US20100256371A1 (en) * 2009-04-02 2010-10-07 Glenmark Processes for the preparation of bosentan and its intermediates thereof
CN102421770A (zh) 2009-04-13 2012-04-18 桑多斯股份公司 制备内皮素受体拮抗剂(波生坦)的方法
US8455522B2 (en) 2009-05-15 2013-06-04 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
JP5659224B2 (ja) 2009-05-15 2015-01-28 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリールピリジン
MX2011012628A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
ES2582395T3 (es) 2009-05-28 2016-09-12 Novartis Ag Derivados aminobutíricos sustituidos como inhibidores de neprilisina
WO2011024056A2 (en) 2009-08-27 2011-03-03 Aurobindo Pharma Limited An improved process for the preparation of bosentan
CA2781541A1 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Crystalline forms of bosentan salt and processes for their preparation
CN102712589B (zh) 2009-11-17 2015-05-13 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN102666535B (zh) 2009-11-30 2015-02-25 诺华股份有限公司 作为醛固酮合酶抑制剂的咪唑衍生物
US20120283190A1 (en) 2009-12-09 2012-11-08 Institut National de la Santé et de la Recherche Medicale (INSERM) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
EP2368884A1 (en) 2010-03-25 2011-09-28 Laboratorios Lesvi, S.L. Process for the preparation of bosentan
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
US9139537B2 (en) 2010-08-11 2015-09-22 Megafine Pharma(P) Ltd. Process for preparation of bosentan
PL2621909T3 (pl) * 2010-10-01 2019-05-31 Zach System Spa Sposób wytwarzania monohydratu Bosentanu i jego związków pośrednich
WO2012056468A1 (en) 2010-10-13 2012-05-03 Matrix Laboratories Ltd A process for the preparation of bosentan
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US20130303762A1 (en) 2010-12-03 2013-11-14 Jayaraman Venkat Raman Process for preparing bosentan
ES2386173B1 (es) * 2011-01-13 2013-06-25 Urquima, S.A. Proceso de preparación de un antagonista del receptor de la endotelina
EP2696857A1 (en) 2011-04-11 2014-02-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising bosentan
KR20140028078A (ko) * 2011-05-23 2014-03-07 온코 바이오메디컬 테크놀로지 (수조우) 코., 엘디디. 씨디씨42 억제제 및 이의 용도
WO2013098577A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of bosentan
US20130245259A1 (en) 2012-03-16 2013-09-19 Natco Pharma Limited Process for the preparation of bosentan monohydrate
ITMI20120701A1 (it) 2012-04-27 2013-10-28 Dipharma Francis Srl Procedimento per la purificazione di un composto benzensolfonammidico
CN104487057A (zh) 2012-05-11 2015-04-01 韩诺生物制药株式会社 波生坦控释口服制剂
JP2015521594A (ja) 2012-06-12 2015-07-30 カディラ ファーマシューティカルズ リミテッド ボセンタンの製造方法
EP2890694A4 (en) 2012-08-31 2015-12-30 Rao Davuluri Ramamohan 4-TERT-BUTYL-N- [6- (2-HYDROXYETHOXY) -5- (2-METHOXYPHENOXY) -2 (2-PYRIMIDINYL) -PYRIMIDIN-4-YL) -BENZENESULFONAMIDE SODIUM
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
KR102004422B1 (ko) 2012-12-20 2019-07-26 제일약품주식회사 보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
CN103554037B (zh) * 2013-11-08 2015-03-18 南京靖龙药物研发有限公司 一种波生坦代谢物羟基波生坦的制备方法
WO2016116842A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
CA3024180A1 (en) * 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP4132932A4 (en) 2020-04-07 2024-04-17 Syndax Pharmaceuticals, Inc. COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
TWI833430B (zh) * 2021-11-08 2024-02-21 大陸商正大天晴藥業集團股份有限公司 氮雜聯苯類化合物及其應用
US20250228835A1 (en) * 2024-01-12 2025-07-17 Rectify Pharmaceuticals, Inc. Pyridinyloxypyridines and related compounds and their use in treating medical conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545944A1 (de) * 1964-06-19 1969-12-11 Hoffmann La Roche Verfahren zur Herstellung von neuen Sulfonamiden der Pyrimidinreihe
AU6623690A (en) * 1990-10-29 1992-05-26 Ibrahim Raouf Shimi Novel sulfamide derivatives, a method for obtaining them and their use as a drug

Also Published As

Publication number Publication date
KR930000489A (ko) 1993-01-15
TW222625B (enExample) 1994-04-21
SK279006B6 (sk) 1998-05-06
IE921920A1 (en) 1992-12-16
RO111268B (ro) 1996-08-30
IS3877A (is) 1992-12-14
DE59209872D1 (de) 2000-11-23
HU9201930D0 (en) 1992-08-28
KR100235507B1 (ko) 1999-12-15
NO2002012I2 (no) 2005-09-26
JPH05222003A (ja) 1993-08-31
IS2054B (is) 2005-10-14
AU1812192A (en) 1992-12-17
EP0526708B1 (de) 2000-10-18
EP0526708A1 (de) 1993-02-10
DE10299047I1 (de) 2003-03-27
PT526708E (pt) 2001-04-30
GR3035162T3 (en) 2001-04-30
ZA924126B (en) 1993-02-24
ES2152222T3 (es) 2001-02-01
CY2306B1 (en) 2003-11-14
AU653604B2 (en) 1994-10-06
NO922323L (no) 1992-12-14
BG60831B2 (bg) 1996-04-30
NO303826B1 (no) 1998-09-07
ATE197044T1 (de) 2000-11-15
HUT63152A (en) 1993-07-28
ES2152222T4 (es) 2011-10-28
FI922746A0 (fi) 1992-06-12
HU221203B1 (en) 2002-08-28
FI112216B (fi) 2003-11-14
DK0526708T3 (da) 2001-02-12
FI922746L (fi) 1992-12-14
NL300097I1 (nl) 2002-11-01
IL102138A (en) 1996-09-12
DE10299047I2 (de) 2009-11-05
CZ281434B6 (cs) 1996-09-11
HU211683A9 (en) 1995-12-28
IL102138A0 (en) 1993-01-14
NZ243074A (en) 1994-11-25
NO922323D0 (no) 1992-06-12
CA2071193C (en) 1998-08-25
US5292740A (en) 1994-03-08
SG54209A1 (en) 1998-11-16
CS180492A3 (en) 1992-12-16
CA2071193A1 (en) 1992-12-14
DZ1587A1 (fr) 2002-02-17
MX9202747A (es) 1994-05-31
EE03028B1 (et) 1997-08-15
RU2086544C1 (ru) 1997-08-10
CY2004005I1 (el) 2009-11-04
LU90976I2 (fr) 2002-12-16
BR9202219A (pt) 1993-02-02
LU90975I2 (fr) 2002-12-16
CY2004005I2 (el) 2016-08-31

Similar Documents

Publication Publication Date Title
JPH0730042B2 (ja) スルホンアミド類および薬物としてのそれらの使用
KR100238366B1 (ko) 설폰아미드 및 이를 함유하는 약제학적 제제
EP0959072B1 (en) Sulfonamide derivative and process for preparing the same
US5420129A (en) Phenylsulfonylamide pyrimidine
RU2162084C2 (ru) Сульфонамиды и фармацевтический препарат
JP2004509874A (ja) 新規なアリールアルカン−スルフォンアミド類
JP3067131B2 (ja) 医薬組成物
RU2083567C1 (ru) Производные арилсульфонамида или их соли и фармацевтическая композиция, проявляющая ангиопротекторное, антигипертензивное и вазоспазмолитическое, в частности противоишемическое, действие
JPH10226649A (ja) 医薬組成物
JPH10194972A (ja) 医薬組成物
SA92130049B1 (ar) سلفوناميدات sulphonamides
SI9200268A (sl) Uporaba sulfonamidov za pripravo zdravil in novi sulfonamidi

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

S202 Request for registration of non-exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R315201

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S202 Request for registration of non-exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R315201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S202 Request for registration of non-exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R315201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080405

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090405

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090405

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100405

Year of fee payment: 15

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110405

Year of fee payment: 16

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130405

Year of fee payment: 18

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140405

Year of fee payment: 19

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees